对家族性阿尔茨海默氏病遗传学的另一个观点
1Alzheimer's Disease Genetics Laboratory, School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.
Journal of Alzheimer's disease : JAD
|September 18, 2023
概括
对于阿尔茨海默病的粉样蛋白级联假设是有效的,但往往被误解. 粉样蛋白前体蛋白 (APP) 的特定片段的活性增加,而不是粉样β (Aβ),是致病的关键驱动因素.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 粉样蛋白级联假说是阿尔茨海默氏症 (AD) 病原学的领先理论.
- 目前的解释往往过度强调粉样β (Aβ) 作为主要驱动者的作用.
研究的目的:
- 用遗传和概率论证重新评估粉样蛋白级联假设.
- 为了确定AD病变发生的关键分子决定因素.
- 提出一个精细的AD病因学模型.
主要方法:
- 分析与家族AD突变相关的遗传数据.
- 基于概率和节的推理.
- 对APP,PSEN1,PSEN2和γ-分泌酶功能的现有文献的审查.
主要成果:
- 粉样前体蛋白 (APP) 的βCTF (C99) 片段的活性增加被认为是关键的致病决定因素.
- 在APP,PSEN1和PSEN2中的家族AD突变汇聚在破坏内酶体酸化和线粒体功能上.
- 铁稳定性受损和伪低氧是拟议机制的核心.
结论:
- 粉样蛋白级联假设是有效的,但需要一个更狭窄的解释,专注于APP处理.
- 普列尼林突变影响全蛋白功能和γ-分泌酶复合物的稳定性,而不仅仅是Aβ长度比.
- 氧化应激, lysosomal 功能受损和神经炎症是AD进展的关键因素.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Human Genetics
610
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
610
Genetic Lingo
103.1K
Overview
103.1K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Biological Causes of Schizophrenia
77
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
77
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K


